Analysis of melanoma tumor biopsies before treatment by anti-PD1 therapy identifies a T-cell inflamed TME –characterized by an active IFN-γ related profile, cytotoxic effector molecules and cytokines– as positively associated with a clinical benefit (40). This evidence concerns the gene IFNG and melanoma.